Zhonghua Wang

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

Xichun Hu, Jian Zhang, Binghe Xu et al. · International Journal of Cancer · 2014 · 269 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

Xichun Hu, Jun Cao, Wenwei Hu et al. · BMC Cancer · 2014 · 235 citations · Full text

Medicine, Oncology, Pharmacology +17

Adipocytokines and Lipid Levels in Ames Dwarf and Calorie-Restricted Mice

Zhonghua Wang, Khalid Al-Regaiey, Michał M. Masternak et al. · The Journals of Gerontology Series A · 2006 · 100 citations

Life Sciences, Endocrinology, Nutritional Sciences +17

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Song‐Yang Wu, Ying Xu, Li Chen et al. · Molecular Cancer · 2022 · 97 citations · Full text

Life Sciences, Immunology, Oncology +17

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Li Chen, Yi‐Zhou Jiang, Song‐Yang Wu et al. · Clinical Cancer Research · 2022 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17